Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving…
Read More...
Read More...